Related Experiment Video
Updated: Aug 18, 2026
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
SCF(beta-TrCP1) controls Smad4 protein stability in pancreatic cancer cells
Mei Wan1, Jin Huang, Nirag C Jhala
1Department of Pathology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. mwan@path.uab.edu
Abstract:
Smad4, also known as deleted in pancreatic carcinoma locus 4 (DPC4), is a critical co-factor in signal transduction pathways activated by transforming growth factor (TGF)-beta-related ligands that regulate cell growth and differentiation. Mutations in Smad4/DPC4 have been identified in approximately 50% of pancreatic adenocarcinomas. Here we report that SCF(beta-TrCP1), a ubiquitin (E3) ligase, is a critical determinant for Smad4 protein degradation in pancreatic cancer cells. We found that F-box protein beta-TrCP1 in this E3 ligase interacted with Smad4 and that SCF(beta-TrCP1) inhibited TGF-beta biological activity in pancreatic cancer cells by decreasing Smad4 stability. Very low Smad4 protein levels in human pancreatic ductal adenocarcinoma cells were observed by immunohistochemistry. By analyzing pancreatic tumor-derived Smad4 mutants, we found that most point-mutated Smad4 proteins, except those within or very close to a mutation cluster region, exhibited higher interaction affinity with beta-TrCP1 and significantly elevated protein ubiquitination by SCF(beta-TrCP1). Furthermore, AsPC-1 and Caco-2, two cancer cell lines harboring Smad4 point mutations, exhibited rapid Smad4 protein degradation due to the effect of SCF(beta-TrCP1). Both Smad4 levels and TGF-beta signaling were elevated by retrovirus-delivered beta-TrCP1 siRNA in pancreatic cancer cells. Therefore, inhibition of Smad4-specific E3 ligase might be a target for therapeutic intervention in pancreatic cancer.
Insights
The SCF(beta-TrCP1) E3 ligase degrades Smad4 protein, a key factor in pancreatic cancer. Inhibiting this ligase may offer a new therapeutic strategy for pancreatic cancer by stabilizing Smad4.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Background:
- Smad4 (Deleted in Pancreatic Carcinoma Locus 4) is crucial for TGF-beta signaling, regulating cell growth and differentiation.
- Mutations in Smad4 are found in about 50% of pancreatic adenocarcinomas, highlighting its role in pancreatic cancer.
Purpose of the Study:
- To investigate the role of the SCF(beta-TrCP1) ubiquitin ligase in Smad4 protein degradation in pancreatic cancer cells.
- To explore the potential of targeting Smad4 degradation pathways for pancreatic cancer therapy.
Main Methods:
- Investigated the interaction between SCF(beta-TrCP1) and Smad4 using biochemical assays.
- Analyzed Smad4 protein levels and stability in pancreatic cancer cell lines with and without Smad4 mutations.
- Utilized immunohistochemistry to assess Smad4 protein levels in human pancreatic tumors.
- Employed beta-TrCP1 siRNA to modulate Smad4 levels and TGF-beta signaling.
Main Results:
- SCF(beta-TrCP1) directly interacts with Smad4, targeting it for degradation and inhibiting TGF-beta signaling in pancreatic cancer.
- Pancreatic cancer cells exhibit low Smad4 protein levels due to SCF(beta-TrCP1)-mediated degradation.
- Most Smad4 point mutations increase interaction with beta-TrCP1, leading to enhanced ubiquitination and degradation.
- Silencing beta-TrCP1 using siRNA increased Smad4 levels and TGF-beta signaling in pancreatic cancer cells.
Conclusions:
- SCF(beta-TrCP1) is a critical determinant of Smad4 protein stability in pancreatic cancer.
- Targeting Smad4-specific E3 ligases like SCF(beta-TrCP1) presents a potential therapeutic strategy for pancreatic cancer.
Related Concept Videos
01:16TGF - β Signaling Pathway
02:23Abnormal Proliferation